BNGO/ News und Infos Forum: Community User: Ray7

SAN DIEGO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it has completed the first prototype for its next single molecule imaging system for OGM. The prototype is being used to integrate and test the key engineering designs of a new instrument and consumable intended to meet the needs of high volume users. The commercial system based on this prototype is expected to be released in the first half of 2023. We believe OGM provides the most comprehensive, reliable and cost-effective solution for detecting structural variations (SVs). OGM is a workflow comprised of four proprietary stages: (i) ultra-high molecular weight DNA isolation; (ii) sequence-specific DNA labeling; (iii) single molecule linearization & imaging; and (iv) data processing and analysis. The third stage creates the molecule images and sequence motif patterns that are used to reveal SVs. This stage also sets the limit on the number of samples that can be processed per day. The throughput of the current Saphyr system is designed for the volumes encountered by academic medical centers doing standard clinical research in genomics, but large reference laboratories and contract research organizations (CROs) with higher volumes require an instrument with higher throughput capabilities. Compared to the Saphyr system, which images DNA at a rate of approximately 205 Gbp per hour, the new system is expected to image nearly 820 Gbp per hour. The new instrument is designed to be configurable into an array of up to four instruments processing samples in parallel approximately six months after initial release. Other anticipated features of the new system include a new consumable design, higher capacity carousel for staging samples to be imaged and updated optical components all in a space-efficient benchtop footprint. The new imaging system will also incorporate features designed to make high throughput workflows more flexible, allowing for data collection to start without needing to wait for multiple samples being available, enabling high-coverage cancer experiments to be run next to lower coverage constitutional experiments and the ability to prioritize samples to be run ahead of all others. This flexibility is expected to surpass that of peer sequencing systems, where getting this flexibility often means waiting for enough samples to fill a flow cell or paying a significant per sample premium to have a sample consume more of a consumable. Erik Holmlin, PhD, president and CEO of Bionano said, “I want to congratulate our team for finishing this prototype on schedule. With expected integration of OGM into NxClinical in 2022, the leading software solution for visualization, interpretation and reporting of single nucleotide variants and copy number variants from next-generation sequencing and microarrays, we believe this new system and consumable will be the next major additions to our list of products for the growing community of OGM users. I am impressed with the innovation our team has brought to the project and I am eagerly awaiting their progress in 2022.” sind

https://investorplace.com/2021/12/the-critics-are-wrong-about-bngo-stock/?mod=mw_quote_news

https://www.chartmill.com/stock/quote/BNGO/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=BNGO&utm_campaign=social_tracking

https://wallstreetfacts.com/2021/12/01/new-data-is-out-for-bngo-2/

From Kevin De Greeter (Oppenheimer) Bionano (BNGO) might have reported a wider loss than expected in Q3, but that factor is of less importance to Oppenheimer’s Kevin DeGeeter. The life sciences company reported a net loss of $20.75 million, a 92% increase on the same period last year. However, DeGeeter believes the company surpassed expectations on the three most important metrics. First off, for the 6th consecutive quarter, Bionano posted a beat on the top-line, with revenue increasing by 112% year-over-year to $4.7 million vs. the Street’s call for $4.2 million. There was even better growth on the consumables front, as the company sold 3,969 nanochannel array flow cells, a 122% uptick and amounting to the best quarterly haul ever. Street was expecting 3,313. Lastly, and most importantly, the company added 20 new installations of its optical genome mapping (OGM) system Saphyr, someway above the consensus estimate of 14. This brought Saphyr’s total placements by the end of September to 141, also “well above” DeGeeter’s estimate of 135 and keeping the company on track to improve on its guidance of 150 by the end of the year. As such, DeGeeter raised his forecast to 156 placements from the prior 150. Saphyr’s ongoing success is key to DeGeeter’s long-term outlook; “We continue to view installed systems as best predictor of future revenue growth,” the 5-star analyst explained. During the height of the pandemic, given access restrictions, Bionano regularly shipped more units than could be installed. Although the trend has been “normalizing” somewhat, in the quarter the company still shipped 24 units while installing only 20. Accordingly, DeGeeter sees the completion of installs on shipped units plus the $132,000 from annual contracts on new reagent rentals once placed as “providing healthy visibility on near-term growth.” The company also believes that the prototype of the next-gen Saphyr will be completed this quarter, signaling to DeGeeter that a 2023 introduction remains on track. Additionally, due to equity raises made during Q1, the company’s cash position has significantly improved; Bionano’s balance sheet boasted $326.1 million in cash and short-term investments at the end of the quarter, compared to $38.4 million at the end of last year. All in all, there’s no change to DeGeeter’s rating which stays an Outperform (i.e., Buy) or price target, which remains at $14. There’s upside potential of an impressive 136% from current levels. Other analysts are no less confident; 2 additional Buys make for a Strong Buy consensus rating; shares are anticipated to more than double in the year ahead, given the average price target clocks in at $12.

Bionano Genomics, Inc. announced today that, in accordance with Nasdaq Listing Rule 5635(c)(4), the Compensation Committee of its Board of Directors granted the following non-qualified stock options pursuant to the company’s 2020 Inducement Plan to new employees as an inducement material to such employees entering into employment with Bionano: to Soheil Shams, Bionano’s Chief Informatics Officer, an option to purchase up to 400,000 shares of common stock; and to 18 employees in connection with Bionano’s acquisition of BioDiscovery, Inc., options to purchase up to an aggregate of 454,000 shares of common stock. The shares subject to each option will vest over four years, with 25% of the shares subject to each option vesting on the one-year anniversary of the vesting commencement date of October 18, 2021 and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each new employee’s continuous service through each applicable vesting date. Each of the foregoing stock options has an exercise price of $5.40 per share, which is equal to the closing price of Bionano’s common stock on November 1, 2021, the grant date.

As a guy that’s taken down his share of tenbagger growth stocks, Navellier knows the importance of buying when others are selling — or when others are shorting, in the case of BNGO. Shares of Bionano currently maintain short interest of 16%. Bears might reasonably take comfort knowing this past quarter’s transformational sales only amounted to revenue of $3.9 million. When compared to BNGO’s $1.42 billion valuation, it produces a frothier-looking 80x sales multiple. In a vacuum, it’s easy to understand what the bears might be seeing. The thing is that, despite the multiple compression in shares, BNGO stock remains superficially expensive-looking. But under the microscope, Bionano is a small-cap company that’s beginning to sell critical technology in a genomics market. With obviously huge growth prospects and plenty of cash in the bank, the company’s bears could reasonably be betting on the wrong pony. As a group, they’ve been proven painfully wrong more than once. Think about Netflix (NASDAQ:NFLX), Amazon (NASDAQ:AMZN) and more recently, Tesla (NASDAQ:TSLA). Who’s to say it can’t happen again with BNGO stock? There’s Still Hope for Bionano Stock Technically speaking, BNGO stock has a nice-looking area for a durable monthly chart double-bottom pattern to emerge. I can agree with Navellier’s words: “a strong finish to the year might be in store for Binonano and its investors.” Considering all of these factors, there’s no reason to overlook Bionano’s options market to unlock stronger risk-adjusted profits in BNGO

https://finance.yahoo.com/news/nuprobe-global-adopts-bionano-saphyr-120000335.html

https://investorplace.com/2021/08/bngo-stock-will-soar-as-the-companys-diagnostic-system-catches-on/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+InvestorPlace+%28InvestorPlace%29

https://insider-analysis.com/search_whales.php?ticker=TABLE_BNGO

https://finance.yahoo.com/news/bionano-optical-genome-mapping-reveals-120000592.html

https://www.streetinsider.com/dr/news.php?id=18651738&gfv=1

https://www.cnbc.com/2021/07/06/cramer-lightning-round-radnet-is-a-good-situation.html